Indeed, both mouse and human HR+ breast cancer cells secreted CCL2 in response to P. Moreover, CCL2 neutralization with a specific monoclonal antibody not only improved the therapeutic effects of P+T against M/D-driven mammary carcinomas, but also limited their infiltration by IL17-producing γδ T cells. The gene discussed is IL17A; the disease is breast cancer.